PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 28, 2026International Journal of Clinical Practice0 citationsOpen Access

Molecular Subtyping of Hepatocellular Carcinoma by T Cell–Mediated Killing Genes: A Multiomic Framework for Prognostic Stratification and Precision Therapeutics

View Full Paper
LLLong LiuBTBo TangFMFeng Ma

Key Points

  • To investigate the role of genes regulating tumor cell sensitivity to T cell-mediated killing in the molecular subtyping of hepatocellular carcinoma (HCC).
  • Integrated multiomics data from TCGA-LIHC to identify eight prognostic GSTTKs.
  • Utilized consensus clustering and UMAP for subtype definition validated by nearest template prediction algorithm.
  • Analyzed genomic alterations, immune infiltration, and drug sensitivity across independent cohorts.
  • Identified three GSTTK subtypes with distinct molecular and clinical characteristics, with p < 0.001 across validation cohorts.
  • GSTTK2 subtype exhibited an immune-excluded phenotype and poorest prognosis, enriched for TP53 mutations and high tumor mutational burden.
  • Vinorelbine showed enhanced cytotoxicity in GSTTK2 cells compared to other subtypes (p < 0.01).

Abstract

Background Hepatocellular carcinoma (HCC) is characterized by substantial heterogeneity and poor prognosis despite therapeutic advancements. Genes regulating tumor cell sensitivity to T cell–mediated killing (GSTTKs) have been implicated in immune evasion, yet their potential role in HCC molecular subtyping remains to be fully elucidated. Methods Multiomics data from TCGA‐LIHC were integrated to identify eight prognostic GSTTKs through stringent selection criteria. Consensus clustering and UMAP were employed to define subtypes, with validation performed via nearest template prediction (NTP) algorithm across five independent cohorts. Genomic alterations, immune infiltration, pathway enrichment, and drug sensitivity were systematically analyzed. HBV infection associations were evaluated in four cohorts with complete etiology records. Subtype‐specific drug responses were experimentally assessed using representative HCC cell lines. Results Three GSTTK subtypes were identified with distinct molecular and clinical characteristics, showing consistent prognostic trends across validation cohorts ( p 0.05), suggesting that the classification may reflect tumor‐intrinsic molecular features, though the contribution of viral etiology to early tumor evolution cannot be excluded. Computational analysis predicted potential subtype‐specific therapeutic vulnerabilities, and experimental validation indicated that vinorelbine exhibited enhanced cytotoxicity in GSTTK2‐representative cells compared to other subtypes ( p < 0.01). Conclusion This study proposes a GSTTK‐based molecular classification integrating genomic, metabolic, and immune features, which may offer prognostic value and inform therapeutic stratification. Further prospective validation is warranted to establish clinical utility.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Liu et al. (2026) studied this question.

synapsesocial.com/papers/69f04e9b727298f751e727b9https://doi.org/10.1155/ijcp/6800480
Ask AI
Helpful
Bookmark
Share
View Full Paper